Results 81 to 90 of about 8,771 (219)

Erosion Regression in Patients with RA After Upadacitinib-A Pilot Study Using High Resolution Peripheral Quantitative Computed Tomography

Journal of Clinical Rheumatology and Immunology
Background: Janus kinases inhibitor (JAKi) is a potent drug in treating patients with rheumatoid arthritis (RA). However, the effect of JAKi on finite structural changes remained uncertain.
Isaac T Cheng, Ho So, Evelyn H Chow, Qihan Wu, Martin Li, Vivian W Hung, Ling Qin, Chun Kwok Wong, Lai Shan Tam   +8 more
doaj   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

A Case of Refractory Vernal Keratoconjunctivitis Showing Improvement after the Administration of Upadacitinib for the Treatment of Atopic Dermatitis

Diagnostics
Vernal keratoconjunctivitis is a persistent allergic ocular disease predominantly mediated by the T-helper 2 lymphocyte-associated immune response. The standard therapeutic approaches for vernal keratoconjunctivitis include topical corticosteroids and ...
Yoshihito Mima, Eri Tsutsumi, Tsutomu Ohtsuka, Ippei Ebato, Yukihiro Nakata, Taro Kubota, Yuta Norimatsu   +6 more
doaj   +1 more source

Therapeutic outcomes across Janus kinase inhibitors in prurigo nodularis [PDF]

Background Prurigo nodularis (PN) is a debilitating skin condition. When inadequate disease control is achieved or other systemic therapies are contraindicated, Janus kinase inhibitors (JAKis) may be considered, although real-world evidence remains ...
Alessandra Narcisi, Andrea Bombelli, Angelo V Marzano, Anna Balato, Benedetta Galli, Carlotta Gurioli, Cataldo Patruno, Caterina Foti, Elena Pezzolo, Elia Esposto, Emanuele Cozzani, Enzo Errichetti, Eustachio Nettis, Fabrizio Guarneri, Francesca Barei, Francesca Caroppo, Francesca di Vico, Franco Rongioletti, Giampiero Girolomoni, Gianluca Avallone, Gianluca Tavoletti, Ilaria Trave, Katharina Hansel, Ketty Peris, Laura Bonzano, Laura Calabrese, Laura Del Regno, Laura Lazzeri, Luca Mastorino, Luca Stingeni, Luca Valtellini, Luigi Gargiulo, Maddalena Napolitano, Maria C Fargnoli, Maria Esposito, Mariateresa Rossi, Martina Maurelli, Michela Ortoncelli, Niccolò Gori, Paola Savoia, Paolo Calzari, Roberta Giuffrida, Serena Lembo, Silvia M Ferrucci, Simone Ribero, Stefano Caccavale, Sveva Lenti   +46 more
core   +1 more source

One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study

Alimentary Pharmacology &Therapeutics, EarlyView.
In a real‐world cohort of patients with highly refractory perianal Crohn's disease, upadacitinib induced clinical remission at 12 months in 26% of patients with fistulizing disease and 25% of those with isolated anal ulcerations. ABSTRACT Introduction Upadacitinib (UPA) is effective for treating luminal Crohn's disease (CD), but data on perianal CD ...
Nicolas Richard, Philippe Seksik, Romain Altwegg, Maria Nachury, David Laharie, Stéphane Nancey, Benoît Coffin, Anne‐Laure Pelletier, Mathieu Uzzan, Aurélien Amiot, Morgane Amil, Lucine Vuitton, Mathurin Fumery, Anne Bozon   +13 more
wiley   +1 more source

Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2)

Dermatology and Therapy
Introduction The Aiming High in Eczema/Atopic Dermatitis (AHEAD) guidelines recommend achieving minimal disease activity (MDA) in atopic dermatitis (AD), defined as simultaneous achievement of optimal treatment targets for at least one clinician- and one
Jonathan I. Silverberg, Melinda Gooderham, Norito Katoh, Valeria Aoki, Andrew E. Pink, Yousef Binamer, Brad Glick, Petra Staubach, Brian Calimlim, Chao Li, Ayman Grada, Alvaro Moreira, Wan-Ju Lee, Andreas Wollenberg   +13 more
doaj   +1 more source

Predictive factors for responders to upadacitinib treatment in patients with atopic dermatitis

Journal of Dermatological Treatment
Background Janus kinase 1 inhibitor upadacitinib is therapeutically effective for atopic dermatitis (AD). However, predictive factors for high responders to upadacitinib have not been established in real-world clinical practice.Objectives To identify ...
Teppei Hagino, Mai Yoshida, Risa Hamada, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda   +5 more
doaj   +1 more source

Treatment of disseminated granuloma annulare with pulse therapy upadacitinib [PDF]

Granuloma annulare (GA) is an idiopathic inflammatory skin condition with a chronic and unpredictable course. Although localized GA is usually cleared with topical or systemic corticosteroids, generalized GA is often difficult to treat owing to the lack ...
Bialick, Mallorie, Kabigting, Filamer, Smithem, Cassi, Trees, Alanna   +3 more
core   +1 more source

The Upadacitinib - New Janus Kinase Inhibitor - Literature Review [PDF]

Atopic dermatitis (AD) is a chronic, recurrent dermatosis that affects an increasing percentage of the population. It usually affects children and resolves spontaneously, however, symptoms can persist into adulthood and even appear de novo later in life.
Frańczuk, Agata, Grzelka, Michalina, Głoskowska, Julia, Głuszczyk, Agnieszka, Karkos, Patrycja, Kopczyńska, Ewelina, Kuleta, Katarzyna, Makłowicz, Aleksandra, Plizga, Jakub, Szpulak, Angelika   +9 more
core   +1 more source

Treatment of atopic dermatitis with upadacitinib: adcare single center experience

Frontiers in Medicine
IntroductionThe role of upadacitinib in the management of moderate to severe atopic dermatitis seems promising, but more data on its efficacy and safety are needed.
Daria S. Fomina, Daria S. Fomina, Olga A. Mukhina, Valeria I. Mikhailova, Marina S. Lebedkina, Elizaveta L. Sedova, Elena N. Bobrikova, Olga G. Elisyutina, Olga G. Elisyutina, Elena S. Fedenko, Tair T. Nurpeisov, Tair T. Nurpeisov, Alexander V. Karaulov, Mar’yana A. Lysenko, Mar’yana A. Lysenko, Luis Felipe C. Ensina   +15 more
doaj   +1 more source